OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC have reported the sale of 292,952 shares of common stock belonging to Sion Therapeutics, Inc. (NASDAQ: SION). According to a Form 4 filing submitted to the Securities and Exchange Commission on May 11, 2026, these transactions were completed through multiple trades occurring between May 7 and May 11, 2026.
The total value of the liquidated shares is estimated at $13.36 million, with individual transaction prices ranging from a low of $44.58 to a high of $46.22 per share. The specific breakdown of the divestments is as follows:
- On May 7, 2026, 48,546 shares were sold at a price of $44.61 per share.
- On May 8, 2026, 59,767 shares were sold at a price of $44.58 per share.
- On May 11, 2026, 184,639 shares were sold at a price of $46.22 per share.
Following these sales, the reporting entities maintain an indirect holding of 2,671,822 shares of Sion Therapeutics common stock. The SEC filing clarifies the complex relationship between the entities: the securities are held of record by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC acts as the general partner for OPI VIII, while OrbiMed Advisors LLC serves as the managing member of GP VIII. Consequently, GP VIII and OrbiMed Advisors may be viewed as possessing investment and voting power over the shares held by OPI VIII. However, members of the OrbiMed Advisors management committee, specifically Carl L. Gordon, Sven H. Borho, and W. Carter Neild, have disclaimed beneficial ownership except for any pecuniary interest they may hold.
Notably, Peter A. Thompson, a member of OrbiMed Advisors, holds a position on the board of directors for Sion Therapeutics. This sale comes at a time of significant market momentum for SION. The stock is currently trading near its 52-week high of $48.45, representing a substantial gain of 273% over the last year. In just the past week, the stock has seen a 14% return, bringing the company's total market capitalization to approximately $2 billion.
Key Market Drivers and Sector Impact
Clinical Development Milestones: The biotechnology sector is heavily influenced by clinical trial outcomes. Sion Therapeutics recently reached a milestone by completing enrollment in its Phase 2a clinical trial, known as PreciSION CF. This study investigates the efficacy of SION-719, an investigational treatment for cystic fibrosis, when used in combination with Trikafta, which is the standard treatment currently available. Data from this trial is anticipated to be released in the summer of 2026.
Financial Position and Analyst Outlook: The healthcare and biotech markets are also responding to Sion's underlying financials and analyst sentiment. The company ended its 2025 fiscal year with $310.3 million in cash, a level that supports a projected cash runway extending until 2028. While the company remains unprofitable, analysts have noted its strong current ratio of 20.61 and its status of holding more cash than debt. This financial health has contributed to positive sentiment from several firms:
- Wedbush initiated coverage with an Outperform rating and a $53 price target.
- Jones Trading maintained a Buy rating and raised its price target to $63, citing PreciSION CF trial progress.
- Guggenheim kept a Buy rating while increasing its price target to $50.
- Citizens issued a Market Outperform rating with a price target of $63.
Risks and Uncertainties
Profitability Timelines: A primary risk for investors in the biotech sector is the path to positive earnings. Despite strong liquidity, Sion Therapeutics remains unprofitable, and current analyst expectations do not foresee the company reaching profitability within this calendar year.
Clinical Trial Dependency: The future valuation of the company is closely tied to the upcoming results from the PreciSION CF trial. Because the efficacy of SION-719 in combination with Trikafta is still being evaluated, there remains uncertainty regarding whether these clinical outcomes will meet expectations when results are published in summer 2026.